Takayuki Katsube
Overview
Explore the profile of Takayuki Katsube including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Katsube T, Nicolau D, Rodvold K, Wunderink R, Echols R, Matsunaga Y, et al.
J Antimicrob Chemother
. 2021 Sep;
76(11):3069.
PMID: 34532730
No abstract available.
12.
Katsube T, Nicolau D, Rodvold K, Wunderink R, Echols R, Matsunaga Y, et al.
J Antimicrob Chemother
. 2021 Aug;
76(11):2902-2905.
PMID: 34383901
Objectives: Lung penetration of cefiderocol, a novel siderophore cephalosporin approved for treatment of nosocomial pneumonia, has previously been evaluated in healthy subjects. This study assessed the intrapulmonary pharmacokinetic profile of...
13.
Katsube T, Wajima T
J Pharmacokinet Pharmacodyn
. 2021 Aug;
48(6):851-860.
PMID: 34347231
In pharmacometrics, understanding a covariate effect on an interested outcome is essential for assessing the importance of the covariate. Variance-based global sensitivity analysis (GSA) can simultaneously quantify contribution of each...
14.
Shimizu R, Katsube T, Wajima T
CPT Pharmacometrics Syst Pharmacol
. 2021 Apr;
10(5):489-499.
PMID: 33797208
Platelets are produced by hematopoietic stem cells via megakaryocytes in the bone marrow and play a critical role in hemostasis. The aim of this study was to develop a new...
15.
Watanabe A, Katsube T
Biopharm Drug Dispos
. 2021 Mar;
42(4):178-187.
PMID: 33724506
Conjugation with lipophilic ligands such as cholesterol and α-tocopherol dramatically improves the delivery and efficacy of antisense oligonucleotides (ASOs) in the liver. To estimate the hepatic ASO concentration and the...
16.
Kawaguchi N, Katsube T, Echols R, Wajima T
Antimicrob Agents Chemother
. 2020 Dec;
65(3).
PMID: 33257454
Cefiderocol is a novel siderophore cephalosporin with antibacterial activity against Gram-negative bacteria, including carbapenem-resistant strains. The standard dosing regimen of cefiderocol is 2 g administered every 8 hours over 3 ...
17.
Kawachi T, Ninomiya M, Katsube T, Wajima T, Kanazu T
Xenobiotica
. 2020 Oct;
51(3):287-296.
PMID: 33125290
The human mass balance of lusutrombopag, an orally bioavailable thrombopoietin (TPO) receptor agonist, was characterised in seven healthy male subjects after a single oral dose of [C]-lusutrombopag (2 mg, 100...
18.
Katsube T, Inoue Y, Fukuhara T, Kano T, Wajima T
Eur J Clin Pharmacol
. 2020 Jul;
76(12):1659-1665.
PMID: 32666123
Purpose: Drug-drug interaction (DDI) potentials of lusutrombopag, a thrombopoietin receptor agonist, on the activity of cytochrome P450 (CYP) 3A and of cyclosporine, which inhibits P-glycoprotein and breast cancer resistance protein,...
19.
Numata K, Tanaka K, Katsube T, Ochiai T, Fukuhara T, Kano T, et al.
Hepatol Res
. 2020 Jul;
50(10):1141-1150.
PMID: 32609920
Aim: Lusutrombopag is approved for thrombocytopenia in chronic liver disease patients planned to undergo invasive procedures. In previous clinical studies, lusutrombopag treatment was stopped in patients with an increase in...
20.
Katsube T, Echols R, Wajima T
Clin Infect Dis
. 2019 Nov;
69(Suppl 7):S552-S558.
PMID: 31724042
Cefiderocol, a novel parenteral siderophore cephalosporin, exhibits potent in vitro activity and in vivo efficacy against most gram-negative bacteria, including carbapenem-resistant strains of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas...